XML 23 R12.htm IDEA: XBRL DOCUMENT
v3.21.1

Intangible Assets, Net | 3 Months Ended
--- | ---
Mar. 31, 2021
Intangible Assets, Net |
Intangible Assets, Net | 6. Intangible Assets, Net As of March 31, 2021, the Company’s finite-lived intangible assets, which totaled $5.0 million, resulted from the capitalization of certain milestone payments made to Ipsen Pharma, S.A.S., or Ipsen, in accordance with the terms of the Company’s license agreement with Ipsen, in connection with the Company’s first commercial sale of IMCIVREE in the U.S. in March 2021. The Company began amortizing its finite-lived intangible assets in March 2021 over IMCIVREE’s initial regulatory exclusivity period. Amortization expense was not material for the three months ended March 31, 2021. Amortization expense will be included in cost of sales on the consolidated statements of operations and comprehensive loss.

X
- References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration